Novo's Pioneering Diabetes Pill Impresses In First Big Study
February 22, 2018 / 10:51 AM / 7 months ago Novo's pioneering diabetes pill impresses in first big study COPENHAGEN/LONDON (Reuters) - The worlds largest diabetes drugmaker, Novo Nordisk, on Thursday presented the first successful data from a large final-stage study of a pill it hopes will transform the diabetes market. FILE PHOTO: The logo of Danish multinational pharmaceutical company Novo Nordisk is pictured on the facade of a production plant in Chartres, north-central France, April 21, 2016. REUTERS/Guillaume Souvant/Pool/File Photo The oral form of the drug, known generically as semaglutide, is crucial for ensuring the groups long-term growth, as price pressure mounts in a crowded market targeting the worlds 450 million diabetics. The new medicine is a threat to Eli Lilly, a key rival in the multibillion-dollar diabetes market. Novo said the first of 10 Phase III trials that are due this year had met its primary goal by demonstrating significant and superior improvements in long-term blood sugar levels compared to a placebo. The trial also showed that the highest of the three tested doses - 3, 7 and 14 mg - demonstrated significant and superior weight loss. While weight loss was also observed for two lower doses, they did not reach statistical significance. Importantly, nausea was not a major problem with the new pill, as some experts had feared. The companys shares rose on the news and traded 3.7 percent higher by 1230 GMT. The once-daily pill belongs to a blockbuster class of treatments known as GLP-1s that stimulate insulin production, the first of which were derived from the venomous bite of North Americas Gila monster lizard. So far, all have been injections. UBS analyst Michael Leuchten said the blood sugar reductions were as good if not better than those a Continue reading >>
- Looking to cure Type 1 diabetes, investors front $114M to launch a pioneering human study at Semma
- Pioneering type 1 diabetes therapy safe
- Type 2 diabetes breakthrough: Scientists create first pill that not only STOPS the condition in its tracks but also helps patients lose weight - and it could be available on the NHS within 3 years
Anthony Anderson's Diabetes Story | Get Real About Diabetes | Novo Nordisk Us
My journey to getting real aboutdiabetes We all have our own diabetes story. The team at Get Real About Diabetes asked me about mine, and here it is. My journey to getting real aboutdiabetes We all have our own diabetes story. The team at Get Real About Diabetes asked me about mine, and here it is. When were you first diagnosed with type 2 diabetes? 2002. I had all the classic symptoms, excessive thirst, constantly going to the bathroom, etc. At one point I drank an absurd amount of water over a couple hours and I knew there was something going on. I didnt take it as seriously as I should have. I took the medicine my health care provider first prescribed, but I didnt commit to diet and being active like I needed to. I kept telling myself that Everything is good in moderation, which was just an excuse to keep eating what I wanted. What made you decide to get real about your diabetes? About 10 years ago my dad passed away from type 2 diabetes complications. That was really tough, especially knowing that if my dad had taken better care of himself, he might still be here. My dad just didnt know what happens when you dont take control of your diabetes. That was a real wake-up call for me. I didnt want to just be a memory for my family, I wanted to be there. So, I vowed right then and there that things would be different, that I would get serious about managing my diabetes. What changes did you make when you decided to get real? Man, I changed a lot. For me, I kind of needed a fresh start, to leave all my old ways behind. I had just moved to New York for a new gigand I decided, Ok, this is it. Its time for the new me. I started with my diet. Al Roker is a good friend of mine and he recommended his nutritionist to me. She helped me cut out unnecessary carbs and gave me an act Continue reading >>
Novo Nordisk Launches The Innovation Challenge Focused On Diabetes Management
Novo Nordisk, a global leader in the diabetes space, is seizing the opportunity to advance care and leverage digital health technology through theNovo Nordisk Innovation Challenge. With support from MATTER, a prominent incubator and innovation hub, Novo Nordisk is challenging start-ups, researchers, entrepreneurs, and students to explore, design; and co-develop digital health solutions for the more than 400 million people living with diabetes worldwide. The first phase of the challenge is an open call to submit creative solutions for diabetes management by October 26. The solution must address one or a combination of the following needs of people living with diabetes: Data Sharing: How might we combine pen injector data with other relevant health data to incentivize and enable patients to actively collect, manage and share their health data with their physician or caregiver? Titration: How might we optimize medicine titration and treatment decisions for people living with diabetes? Dialogue: How might we support the patient and provider dialogue in, and between, clinical visits to improve treatment and care? Health Insights: How might we combine pen injector data with other relevant health data to develop actionable population health insights, targeted treatment care plans and novel business models that support improved care and outcomes? Ten to fifteen semi-finalists will present their ideas at a three-day boot camp with mentors from Novo Nordisk and MATTER in advance of a final pitch competition and demo day on December 5. From there, three to five teams will be chosen to receive $25,000 and a one-year opportunity to build their technology directly with Novo Nordisk, beginning with a 12-week, semi-virtual accelerator program at MATTER. Program participants will build Continue reading >>
Bristol Diabetes Spin-out Acquired By Novo Nordisk For $800m
Bristol Diabetes Spin-Out Acquired By Novo Nordisk For $800M Opinions expressed by Forbes Contributors are their own. I cover the world of deep tech and science startups Bristol University spin-out Ziylo announced today that Danish pharmaceutical Novo Nordisk has acquired all the shares in the company. Novo Nordisk will now have full rights to Ziylo'sglucose binding molecule platform to develop glucose-responsive insulins through astaged acquisition, with a potential deal value that could exceed$800 million.The deal is one of the largest for a Univesity of Bristol spin-out - and over time, could be the largest ever. Designed by Professor Anthony Davis at the University of Bristol, Ziylo's synthetic molecules are able to selectively bind to glucose in the bloodstream.The acquisition supports Novo Nordisk's goal to develop smart insulin, which could potentially revolutionize how we treat diabetes. With the disease being the seventh leading cause of death in the world, there are more than 500 million people living with diabetes worldwide - and the numbers arerising . The development of glucose-responsiveinsulins could remove the risk ofhypoglycemia - incidences when blood sugar is too low which can be caused by too much insulin - which is the main risk associated with insulin therapy, and a huge barrier for achieving optimal control of the patient's glucose. We believe the glucose binding molecules discovered by the Ziylo team together with Novo Nordisk world-class insulin capabilities have the potential to lead to the development of glucose-responsive insulins which we hope can remove the risk of hypoglycaemia and ensure optimal glucose control for people with diabetes, said Marcus Schindler, Senior Vice President, Global Drug Discovery, Novo Nordisk. Novo Nordisk is the Continue reading >>
Log In To Novo Nordisk Innovation Challenge
10-15 semi-finalists will be selected to advance to the incubation phase of the challenge. Each semi-finalist will have the opportunity to further refine and validate your value proposition, business case and product development plans through engagement with experts from across the healthcare ecosystem. If selected for incubation, semi-finalists will have the opportunity to take part in a three-day, in-person bootcamp at MATTER . Network with the healthcare innovation community, attend curated workshops and mentoring sessions specific to your needs and participate in one-on-one sessions with the Novo Nordisk team. As participants develop and refine their concepts throughout incubation, you will have an opportunity to connect with leaders and subject matter experts from Novo Nordisk, as well as clinical, reimbursement and regulatory experts from the MATTER community. The semi-finalists will present to a community of Novo Nordisk executives and community healthcare innovators in Boston, USA. Three to five participanting teams will be selected as finalists and receive a $25,000 cash prize, one-year MATTER membership and a one-year opportunity to further co-develop their solution with Novo Nordisk. The finalists will participate in a 12-week, semi-virtual accelerator where they will build and test their innovation with Novo Nordisk mentors, MATTER staff and stakeholders from across the healthcare community. Winning participants will graduate into the partnering alumni program, where they will have the opportunity to gain greater exposure to Novo Nordisk business units and executives, as well as external investors and partners that could help drive additional co-development opportunities. Continue reading >>
- Pharmaceutical giant Novo Nordisk to invest £115m in a new UK drug research centre in post-Brexit 'vote of confidence'
- FDA approves Novo Nordisk diabetes drug Ozempic
- Macadamian’s My Diabetes Coach™ Receives Runner up and $15,000 in Novo Nordisk’s 2017 HITLAB World Cup of Voice-Activated Technology in Diabetes
Novocare | Patient Assistance Program
The Novo Nordisk Patient Assistance Program (PAP) is based on our commitment to people living with diabetes. The Novo Nordisk PAP provides medicationat no cost to those who qualify. Patients who are approved for the PAP may qualify to receive free diabetes medicine from Novo Nordisk for up to a year.There is no registration charge or monthly fee for participating. Click here for a list of Novo Nordisk products covered by the PAP. You must be a US citizen or legal resident Your total household income must be at or below 300% of the federal poverty level (FPL). Visit the Families USA website , which lists the current FPL guidelines You cannot have any private prescription coverage, such as an HMO or PPO Department of Veterans Affairs (VA) prescription benefits Any federal, state, or local program such as Medicare or Medicaid. Exceptions include: Medicare Part D patients who have spent $1,000 on prescription medicine in the current calendar year Patients who are Medicare eligible and do not have Medicare Part D coverage that have applied for and been denied Extra Help/Low Income Subsidy (LIS). To apply for LIS, please contact the Social Security Administration at 1-800-772-1213 (TTY 1-800-325-0778) or go to socialsecurity.gov/prescriptionhelp Patients who are Medicaid eligible that have applied for and been denied Medicaid How to apply for a free 120-day supply of medicine Continue reading >>
Novo Nordisk To Launch Connected Insulin Pens
Novo Nordisk to launch connected insulin pens Also partners with Dexcom, Glooko and Roche on digital platforms Many diabetes patients have been calling for smart, internet-connected pens to monitor their condition, but the technology has been slow to arrive. Now, Novo Nordisk has announced that it will globally launch two connected insulin pens, which will be able to communicate with continuous glucose monitoring (CGM) systems and blood glucose meters (BGM). This looks to be the start of the long-awaited digital integration, which has been held back by safety concerns, competitive interests and incompatible digital platforms. Novo Nordisks biggest competitors in diabetes injectables are Eli Lilly and Sanofi, but looks to be ahead of its rivals in rolling out a joined-up digital solution, announcing plans to make two durable, connected insulin pens NovoPen 6 and NovoPen Echo Plus commercially available across key markets from early 2019. In addition to demand from patients, healthcare payers, especially in the US, are calling for comprehensive disease management platforms. Responding to this, Novo Nordisk has also signed new partnership agreements with leading players in digital diabetes tech: Dexcom, Glooko and Roche. The partnerships target the advancement of solutions available for people living with diabetes and their healthcare professionals. Building upon its existing work with IBM Watson Health and Glooko, Novo Nordisk aims to seamlessly integrate insulin-dosing data from connected pen devices with its partners' open ecosystems and diabetes management solutions. "Our non-exclusive partnership strategy allows us to integrate with the various digital platforms that people are already using to help manage their diabetes," said Camilla Sylvest, executive vice preside Continue reading >>
- Pharmaceutical giant Novo Nordisk to invest £115m in a new UK drug research centre in post-Brexit 'vote of confidence'
- FDA approves Novo Nordisk diabetes drug Ozempic
- Macadamian’s My Diabetes Coach™ Receives Runner up and $15,000 in Novo Nordisk’s 2017 HITLAB World Cup of Voice-Activated Technology in Diabetes
Xconomy: Eli Lilly Strikes Deal For Diabetes Pill To Gain On Novo Nordisk
Eli Lilly Strikes Deal for Diabetes Pill to Gain on Novo Nordisk Eli Lilly has a blockbuster diabetes drug, dulaglutide (Trulicity), which helps the body make more insulin. But that drug, and others in the same class, are injectables. A number of companies are trying to offer patients a pill alternative. Lilly (NYSE: LLY ) now has a new pill drug candidate in its pipeline. The Indianapolis pharmaceutical giant has acquired rights to a Chugai diabetes drug that is ready to begin Phase 1 studies as a treatment for type 2 diabetes. According to deal terms announced late Thursday, Lilly will pay Tokyo-based Chugai $50 million up front in exchange for worldwide rights to the drug, OWL833. Lilly would be responsible for additional payments if the drug hits development milestones. It would also pay Chugai royalties from sales if the drug reaches the market. The Chugai drug is a GLP-1 receptor agonist. GLP-1 drugs , including Lillys dulaglutide and those on the market from other companies, mimic the effects of a hormone, GLP-1, that the intestine releases in response to food to prompt the body to produce insulin. The newest one is semaglutide (Ozempic), a once-weekly injectable from Novo Nordisk (NYSE: NVO ) that the FDA approved last December. GLP-1 drugs are made from peptides, short chains of amino acids, and must be injected because peptides cant hold up against the bodys digestive system. Novo Nordisk is trying to take diabetes market share from Lilly and others that are selling injectable GLP-1 drugs. But the Danish company is already leading the race to develop a GLP-1 drug in a pill form. In February, it announced that a pill version of semaglutide hit the main goals of its first late-stage study . The most common side effect reported was mild to moderate nausea. Novo Continue reading >>
- Macadamian’s My Diabetes Coach™ Receives Runner up and $15,000 in Novo Nordisk’s 2017 HITLAB World Cup of Voice-Activated Technology in Diabetes
- St. Luke’s Spotlights Critical Link Between Type 2 Diabetes and Heart Disease in Partnership with Boehringer Ingelheim and Eli Lilly and Company
- Eli Lilly Raises Insulin Prices While Supporting People With Diabetes
Novo Nordisk Teaming Up With Startups For Diabetes Challenge, Aiming To Create New Digital Health Tools
The Novo Nordisk Innovation Challenge will ask entrepreneurs and researchers to develop digital tools for diabetes management. (Novo Nordisk Image) More than 100 million people in the U.S. have diabetes or pre-diabetes, making the disease one of the most common and costly health problems in the country. Danish multi-national pharmaceutical company Novo Nordisk and Chicago-based healthcare incubator Matter are looking to take on that problem with the Novo Nordisk Innovation Challenge , which launches Tuesday, Oct. 9. The competition will ask entrepreneurs, researchers and other healthcare innovators to create new digital tools to help diabetes patients achieve better health. It kicks off with two launch events: One at Matter in Chicago and one at Cambia Grove in Seattle, part of TechStars Seattle Startup Week. The Entrepreneurial community in Seattle is thriving, especially in the digital space, with non-traditional partnerships being forged, Thomas Miller, the VP of Novo Nordisks US device research, told GeekWire in a statement. This area is a hub of innovation and we want to tap into that spirit. At the Seattle launch , which takes place from 3 to 5 p.m. Tuesday, Oct. 9, senior engineers from Novo Nordisks Seattle research center will discuss the challenges facing diabetes patients and the kinds of solutions the challenge is hoping to create. They will be joined by Oren Nissim, the CEO of digital diabetes management platform Brook.ai . Challenge participants will have access to patient data, gathered by Novo Nordisk pen injectors, to develop their digital solutions, like digital tools for patients or health IT technologies. Initial applications are due Oct. 26 and a group of ten to fifteen semi-finalists will move on to the next round of the competition. Three to five Continue reading >>
- Pharmaceutical giant Novo Nordisk to invest £115m in a new UK drug research centre in post-Brexit 'vote of confidence'
- Macadamian’s My Diabetes Coach™ Receives Runner up and $15,000 in Novo Nordisk’s 2017 HITLAB World Cup of Voice-Activated Technology in Diabetes
- FDA approves Novo Nordisk diabetes drug Ozempic
Diabetes: Global Trend Undermines Economies, Novo Nordisk Cfo Says
An inexorable global rise in diabetes must be taken "more seriously" by society, according to the chief financial officer at the world's top manufacturer of diabetes drugs. "Our view is that we have got to make it transparent that this is an avalanche of obesity and diabetes which is affecting world economies and we have got to do something about it," Jesper Brandgaard, CFO at Novo Nordisk , told CNBC on Wednesday. He added that while diabetes is a "slow-moving epidemic," it would continue to "undermine" economies around the world unless the international community takes urgent action. At the end of October, a report published by the Cities Changing Diabetes partnership warned that annual diabetes-related health expenditure would spiral to more than $1 trillion in 2045, up from around $775 billion at present. The report, entitled 'Bending the Curve on Urban Diabetes,' stressed that an increase of nearly 40 percent in global expenditure to treat sufferers was a conservative forecast. A leading cause of diabetes is obesity and if that could be reduced by 25 percent over the same period then it would be possible to "bend the curve" on the disease, the report said. "Partnership with cities in changing the way we live, changing the way we manage our health I think that is the long-term solution," Brandgaard said. Continue reading >>
Novo Nordisk's New Type 2 Diabetes Drug Outperforms Eli Lilly's
Novo Nordisk has reported Phase III data that reveal its candidate semaglutide improved glucose control and weight loss in type 2 diabetes when compared with Eli Lillys dulaglutide. The results of the SUSTAIN 7 trial comparing the efficacy of Novo Nordisks semaglutide with Eli Lillys Trulicity (dulaglutide), already in the market, have revealed that Novos drug seems to be better at helping patients with type 2 diabetes control their blood sugar levels and reduce weight. Both drugs are GLP-1 receptor agonists, which induce insulin production and suppress glucagon secretion depending on blood glucose levels. Thus, GLP-1 receptors are currently one of the most coveted targets to treat type 2 diabetes as it can reduce the frequency of injections toone per week. These results further strengthen the potential of semaglutide, which has already been named one of the most valuable pharma R&D projects of the year by Evaluate Pharma , which expects the drug to reach sales of $2.24Bn (1.9Bn) in 2022. The FDA and the EMA are currently evaluating the approval of semaglutide based on results from the SUSTAIN trial, which recruited over 8,000 patients with type 2 diabetes. Continue reading >>
Novo Nordisk Diabetes Center
Novo Nordisk Diabetes Center CentraState Health 2018-07-31T02:20:39+00:00 CentraStates Novo Nordisk Diabetes Center is recognized by the American Diabetes Association for meeting the national standard in diabetes education. The center includes diabetes educators, evidence-based prevention programs, and guidance on self-managing diabetes in partnership with a primary care physician. Star and Barry Tobias Health Awareness Center Visit the CentraState physician finder or call 866-236-8727 to find a primary care physician or endocrinologist near you. Learn more about ongoing support using evidence-based lifestyle changes, diet, and activity to promote weight loss and decrease your risk for developing type 2 diabetes by calling 732-637-6484 . Learn how our diabetes educators can create a customized management program and provide ongoing education and support to help you take charge of your health by calling 732-294-2574 . CentraState Healthcare System is a private,not-for-profit health organization dedicated to excellence, offering the full circle of health and wellness for our community. Continue reading >>
Diabetes Leader Novo Nordisk Is Making Obesity Its Top Priority
Diabetes Leader Novo Nordisk is Making Obesity Its Top Priority Highlights to be presented at Novo Nordisk's Capital Markets Day 2017 Bagsvrd, Denmark, 21 November 2017 - Novo Nordisk will today host a Capital Markets Day where the company will provide updates on its R&D and commercial strategy as well as current market dynamics. Novo Nordisk's ambition is to further expand its leadership in the global diabetes and obesity care markets by discovering, developing and marketing improved insulin and GLP-1 analogues as well as completely new classes of biologics. Furthermore, it is Novo Nordisk's ambition to return to growth in the Biopharm area. Novo Nordisk's R&D strategy and key development projects within diabetes and obesity care as well as the expansion into other serious chronic disease areas Novo Nordisk's commercial strategic priorities as the leader in the global diabetes care market, focusing on maximising insulin growth as well as expanding the GLP-1 market Novo Nordisk's ambition to build the global obesity market Market dynamics in International Operations as well as North America with focus on commercial ambitions and upcoming product launches In addition, the Capital Markets Day 2017 will include break-out sessions covering oral semaglutide and the associated production expansion, the regions in International Operations: Region China and Region AAMEO (Africa, Asia, Middle-East Oceania) as well as an update on the business dynamics in Biopharm Operations. NOVO NORDISK'S R&D STRATEGY AND KEY DEVELOPMENT PROJECTS Novo Nordisk's dedicated R&D strategy will be presented with special focus on key competitive advantages throughout the R&D value chain as well as the expansion into other serious chronic diseases. The presentation will outline the company's R&D strat Continue reading >>
After Fda Approval, Novo Nordisk Eyes 2018 Launch For Once-weekly Diabetes Treatment Ozempic
After FDA Approval, Novo Nordisk Eyes 2018 Launch for Once-Weekly Diabetes Treatment Ozempic Novo Nordisk says it is planning to launch its once-weekly type 2 diabetes treatment Ozempic (semaglutide injection) early in 2018 following approval yesterday by the FDA. Ozempic is a glucagon-like peptide 1 (GLP-1) receptor agonist indicated as an adjunct to diet and exercise. The agency authorized the marketing of Ozempic six weeks after the FDAs Endocrinologic and Metabolic Drugs Advisory Committee recommended approval of the therapy by a 16 to 0 vote with one abstention. The advisory panel heeded the finding of a briefing document by agency staffers that showed favorable results for Ozempic in five Phase III trials (SUSTAIN 1, 2, 3, 4, and 5) and a two-year cardiovascular outcomes trial (SUSTAIN 6) compared to placebo and three competing diabetes treatments: Merck & Co.s Januvia (sitagliptin), Sanofis Lantus (insulin glargine), and AstraZenecas Bydureon (semaglutide injection). Both doses of semaglutide (0.5 mg and 1.0 mg) demonstrated superiority to placebo, in terms of change in HbA1c from baseline, in a monotherapy trial as well as in a trial with basal insulin background therapy, according to the briefing document, in which Jiwei He, Ph.D., summarized the drugs efficacy. Both doses of semaglutide also demonstrated superiority to active comparators sitagliptin and insulin glargine for the HbA1c primary endpoint. Semaglutide 1.0 mg also demonstrated superiority to exenatide ER. In all, Ozempic was evaluated in eight Phase IIIa trials in which more than 8000 adults with type 2 diabetes were enrolled. One of those trials was SUSTAIN 7, for which Novo Nordisk trumpeted positive results in August. In that study, semaglutide showed superiority to Eli Lillys Trulicity (dulaglu Continue reading >>
Novo Nordisk Savings Card
Eligibility and Restrictions: In order to redeem this offer patient must have a valid prescription for the brand being filled. A valid Prescriber ID# is required on the prescription. Patient is not eligible if he/she participates in or seeks reimbursement or submits a claim for reimbursement to any federal or state healthcare program with prescription drug coverage, such as Medicaid, Medicare, Medigap, VA, DOD, TRICARE, or any similar federal or state health care program (each a Government Program), or where prohibited by law. Patient must be enrolled in, and must seek reimbursement from or submit a claim for reimbursement to, a commercial insurance plan. The brand and the prescription being filled must be covered by the patient’s commercial insurance plan. Offer excludes full cash-paying patients. This offer may not be redeemed for cash. By using this offer, you are certifying that you meet the eligibility criteria and will comply with the terms and conditions described herein and will not seek reimbursement for any benefit received through this card. Novo Nordisk’s Eligibility and Restrictions, and Offer Details may change from time to time, and for the most recent version, please visit this webpage. Re-confirmation of information may be requested periodically to ensure accuracy of data and compliance with terms. Patients with questions about the Savings Card offer may call 1-877-304-6855. This offer is valid in the United States and may be redeemed at participating retail pharmacies. Absent a change in Massachusetts law, effective July 1, 2019, the Savings Card will no longer be valid for residents of Massachusetts. Void where taxed, restricted, or prohibited by law. This offer is not transferable and is limited to one offer per person. Not valid if reproduced. C Continue reading >>
- Pharmaceutical giant Novo Nordisk to invest £115m in a new UK drug research centre in post-Brexit 'vote of confidence'
- FDA approves Novo Nordisk diabetes drug Ozempic
- Macadamian’s My Diabetes Coach™ Receives Runner up and $15,000 in Novo Nordisk’s 2017 HITLAB World Cup of Voice-Activated Technology in Diabetes
